BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD DTSTART;VALUE=DATE:20250101 TZNAME:UTC TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:PSI Webinar\nPatient Engagement in Clinical Trials\nDate for We binar: \;Tuesday 13th June \;2:30-3:30pm UK time\nPatients have lo ng been an important part of clinical drug development &ndash\; without th em\, there would be no new medicines. Recently\, there has been a fundamen tal shift in their involvement in the drug development process. Today\, pa tients are highly active in engaging in discussions about their disease\, what they look for in new treatments\, and how clinical trials are designe d and conducted. \nFollowing on from the successful and thought-provoking presentation at last year&rsquo\;s PSI conference by Paul Wicks from Patie ntsLikeMe\, this webinar will continue to explore the ways in which patien ts are influencing the design of new clinical trials. \; We have two s peakers who bring different experience and perspectives on this subject:\n  \;\nDr Cathy Emmas\, \;Partnership Director\, Patient Centricity\ , AstraZeneca\nTitle: Patient-centric medicines development &ndash\; the v alue of online health communities\n\nAbstract: How AstraZeneca&rsquo\;s co llaboration with the PatientsLikeMe is accelerating our ability to generat e the timely and relevant patient insight that enables informed decision m aking within our R&\;D programs. What patient-generated health data tel ls us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.\n\nBiography: Cathy is the Partnership Director in AstraZeneca&rsquo\;s global Patient Centricity tea m where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ab ility to generate the right patient insight that enables informed decision making within our R&\;D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70\, 000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases. \;\n\n\nProfessor Sue Pav itt\, Dental Translational and Clinical Research Unit\, University of Leed s\n\nTitle: Achieving Effective Patient Public Involvement in Clinical Tri als: \;&ldquo\;No research about us without us&rdquo\;\nAbstract: Pati ent public involvement in medicine research and development has gained sig nificant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is importa nt to patients. Achieving effective Patient Public Involvement &\; Enga gement (PPIE ) partnerships enhances the relevance of clinical research an d improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design\, eth ical approval\, conduct and dissemination reach\; collectively building cr oss sector communication and partnerships may enhance market head room lon g term. I will provide a background to patient public involvement and est ablishing effective partnerships and illustrative case examples that suppo rt patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to del iver patient centric medicine R&\;D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials\, by strategically bri nging the patient lived experience to the forefront has the potential to c hange fundamentally how health care is practiced.\nBiography: Sue Pavitt - Prof in Translational &\; Applied Health Research\, University of Leed s. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer ge ne. She worked on the Human Genome Project at UCL\, Oxford and UCSF\, USA. In 1998 she was appointed as the Founding Director of TayRen &ndash\; the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She beca me the Divisional Director at the Clinical Trials Research Unit\, Leeds an d has since gone on to Head the Division for Applied Health and Clinical T ranslation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral &\; Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chai r of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy &\; Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several dise ase areas and is characterized by forging effective\, multi-disciplinary r esearch partnerships between clinicians\, academics\, sometimes industry a nd always patients\; developing methodological sound projects that are pat ient-centric with research questions tailored to clinical priorities to ma ximize impact and patient benefit.\nSue is passionate about patient involv ement in research with >\;30 years&rsquo\; experience. She is the Academ ic Lead for EUPATI-UK &ndash\; European Patient Advocacy for Therapeutic I nnovation- a pan-European Innovative Medicines Initiative\, led by the Eur opean Patients' Forum\, in partnership with patient organizations\, univer sities\, not-for-profit organizations and pharmaceutical companies. EUPATI &rsquo\;s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.\n\nTo access the recording\, please visit the Video-on-Demand Library. DTEND:20170613T153000Z DTSTAMP:20261009T113226Z DTSTART:20170613T143000Z LOCATION: SEQUENCE:0 SUMMARY:Patient Engagement in Clinical Trials Webinar UID:RFCALITEM639271423462347065 X-ALT-DESC;FMTTYPE=text/html:

PSI Webinar
\nPatient Engagement in Clinical Trials
\nDate for We binar: \;Tuesday 13th June \;2:30-3:30pm UK time

\n

Patients have long been an important part of clinical drug development &nd ash\; without them\, there would be no new medicines. Recently\, there has been a fundamental shift in their involvement in the drug development pro cess. Today\, patients are highly active in engaging in discussions about their disease\, what they look for in new treatments\, and how clinical tr ials are designed and conducted.

\n

Following on from the successful and thought-provoking presentation at last year&rsquo\;s PSI conference b y Paul Wicks from PatientsLikeMe\, this webinar will continue to explore t he ways in which patients are influencing the design of new clinical trial s. \; We have two speakers who bring different experience and perspect ives on this subject:

\n

Speaker 1&nbs p\;
\nDr Cathy Emmas\, \;Partnership Directo r\, Patient Centricity\, AstraZeneca
\nTitle: P atient-centric medicines development &ndash\; the value of online health c ommunities
\n
\nAbstract: How A straZeneca&rsquo\;s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enabl es informed decision making within our R&\;D programs. What patient-gen erated health data tells us about symptoms and outcomes that matter to pat ients. Optimisation of clinical trials from the patient perspective.
\n

\n

Biography: Cathy is the Partnership Dir ector in AstraZeneca&rsquo\;s global Patient Centricity team where she lea ds a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to genera te the right patient insight that enables informed decision making within our R&\;D programs and shape healthcare delivery. In the first two year s the collaboration has linked the experiences of over 70\,000 patients in to our lifecycle teams and patient preferences have helped shape 12 clinic al studies across 7 diseases. \;

\n

Sue Pavitt
\n
\nProfessor Sue Pavi tt\, Dental Translational and Clinical Research Unit\, Univer sity of Leeds
\n
\nTitle: Achieving Effect ive Patient Public Involvement in Clinical Trials: \;&ldquo\;No re search about us without us&rdquo\;

\n

Abstract: Patient public involvement in medicine research and development has gaine d significant momentum. Adopting a patient-centric approach in clinical tr ials and research is important to ensure new treatments embrace what is im portant to patients. Achieving effective Patient Public Involvement &\; Engagement (PPIE ) partnerships enhances the relevance of clinical resear ch and improved likelihood of delivering patient benefits. PPI also contri butes to the operational efficiency and success in clinical trial design\ , ethical approval\, conduct and dissemination reach\; collectively buildi ng cross sector communication and partnerships may enhance market head roo m long term. I will provide a background to patient public involvement an d establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choice s. I will introduce EUPATI and its role in meeting the educational needs t o deliver patient centric medicine R&\;D and facilitate partnerships be tween patients-academia and industry in clinical research. We are in an er a of a paradigm shift in patient-centric clinical trials\, by strategicall y bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.

\n

Bio graphy: Sue Pavitt - Prof in Translational &\; Applied Health Research\, University of Leeds. Her PhD was in Human Cancer Genetics and s he had a high profile career working with Prof Sir Walter Bodmer mapping t he first colorectal cancer gene. She worked on the Human Genome Project at UCL\, Oxford and UCSF\, USA. In 1998 she was appointed as the Founding Di rector of TayRen &ndash\; the premier Scottish multidisciplinary Primary C are Research network and the academic focus of her career changed to appli ed health research. She became the Divisional Director at the Clinical Tr ials Research Unit\, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Tran slation and Clinical Research Unit. She is a Specialty lead for the Oral & amp\; Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Netwo rk. She is a Board Member of the MRC-NIHR Efficacy &\; Mechanistic Eva luation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging eff ective\, multi-disciplinary research partnerships between clinicians\, aca demics\, sometimes industry and always patients\; developing methodologica l sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit.\nSue is pa ssionate about patient involvement in research with >\;30 years&rsquo\; experience. She is the Academic Lead for EUPATI-UK &ndash\; European Patie nt Advocacy for Therapeutic Innovation- a pan-European Innovative Medicine s Initiative\, led by the European Patients' Forum\, in partnership with p atient organizations\, universities\, not-for-profit organizations and pha rmaceutical companies. EUPATI&rsquo\;s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.\n

\n

To access the recording\, please visit the Video-on-Demand Library.

END:VEVENT END:VCALENDAR